Autolus Therapeutics plc (AUTL) earnings date
Mar 18, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 27% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 43 days, typically, give or take 19 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Tue, Nov 10, 2026 | before open | 41 | 8-K |
| Q2 FY2026 | Tue, Aug 11, 2026 | before open | 42 | 8-K |
| Q1 FY2026 | Thu, May 14, 2026 | before open | 44 | 8-K |
| Q4 FY2025 | Fri, Mar 27, 2026 | before open | 86 | 8-K |
| Q3 FY2025 | Wed, Nov 12, 2025 | before open | 43 | 8-K |
| Q2 FY2025 | Tue, Aug 12, 2025 | before open | 43 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | before open | 38 | 8-K |
| Q4 FY2024 | Thu, Mar 20, 2025 | before open | 79 | 8-K |
What they guided beta
| Q3 FY2026 | "Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates November 10, 2026 at 7:00 AM EST Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $41.2 million, an increase of 95% year-over-year; now expects full-year 2026 AUCATZYL net product revenue to be at or exceeding upper end of $150 million from prior guidance Gross margin increased to 57%, driven by growing volumes and manufacturing efficiency initiatives Obe-cel clinical development programs progressing with trial enrollment ongoing in lupus nephritis, pediatric ALL and " exhibit |
| Q3 FY2026 | "Obe-cel in pediatric r/r B-ALL The Phase 2 portion of the ongoing CATULUS trial of obe-cel in pediatric patients with relapsed or refractory B-cell precursor ALL (r/r B-ALL) is on track and data are expected to be reported at the end of 2027." exhibit |
| Q3 FY2026 | "Obe-cel in lupus Updated data from the ongoing Phase 1 CARLYSLE trial in patients with severe refractory systemic lupus erythematosus (srSLE) will be presented in a poster at the American College of Rheumatology (ACR) Annual Meeting, today, November 10, 2026." exhibit |
| Q3 FY2026 | "LUMINA, the pivotal Phase 2 study of obe-cel in patients with refractory lupus nephritis (LN) continues enrolling in five countries and the Company expects to report data in 2028." exhibit |
| Q3 FY2026 | "AUTO8 in Light-Chain Amyloidosis The Phase 1 ALARIC trial evaluating AUTO8 in light-chain amyloidosis is ongoing and initial data are expected to be reported at ASH in December 2026." exhibit |
| Q2 FY2026 | "Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates August 11, 2026 at 7:00 AM EDT Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $45.7 million in Q2 2026, an increase of 119% year-over-year FY 2026 net product revenue guidance increased to $140 - $150 million Gross margin increased in Q2 2026, driven by growing volumes and cost reduction initiatives Capital base strengthened through five-year, interest-only credit facility of up to $250 Million with Perceptive Advisors with $75 million funded at close Obe-cel clinical d" exhibit |
| Q2 FY2026 | "Obe-cel in pediatric r/r B-ALL The Phase 2 portion of the ongoing CATULUS trial of obe-cel in pediatric relapsed or refractory (r/r) B-cell precursor ALL (B-ALL) patients is on track and data are expected to be reported at the end of 2027." exhibit |
| Q2 FY2026 | "LUMINA, the pivotal Phase 2 study of obe-cel in patients with refractory lupus nephritis (LN) continues enrolling in five countries and the Company expects to report data in 2028." exhibit |
| Q2 FY2026 | "AUTO8 in Light-Chain Amyloidosis The Phase 1 ALARIC trial evaluating AUTO8 in light-chain amyloidosis is ongoing and initial data are expected to be reported at the end of 2026." exhibit |
| Q2 FY2026 | "An initial $75 million principal amount of notes has been issued by Autolus to Perceptive on July 30, 2026, and an additional $25 million in aggregate principal amount will be available at Autolus’ option for up to six months post-closing." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/AUTL
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/AUTL
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/AUTL/"><img src="https://veritasdata.dev/embed/AUTL.svg" alt="AUTL earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/AUTL/)
Script
<script async src="https://veritasdata.dev/embed/AUTL.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/AUTL"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.